Short Report: Treatment Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal–Bolus Type 1): 2-year results of a randomized clinical trial

@inproceedings{Bode2013ShortRT,
  title={Short Report: Treatment Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal–Bolus Type 1): 2-year results of a randomized clinical trial},
  author={Bruce W Bode and John B Buse and Miles Fisher and S. K. Garg and Michel Marre and Ludwig Merker and Elisabeth Renard and David Russell-Jones and Charlotte Toftmann Hansen and Anshika Rana and Simon R. Heller},
  booktitle={Diabetic medicine : a journal of the British Diabetic Association},
  year={2013}
}
AIMS The goal of this study was to compare the long-term safety and efficacy of the basal insulin analogue, insulin degludec with insulin glargine (both with insulin aspart) in Type 1 diabetes, over a 2-year time period. METHODS This open-label trial comprised a 1-year main trial and a 1-year extension. Patients were randomized to once-daily insulin degludec or insulin glargine and titrated to pre-breakfast plasma glucose values of 3.9-4.9 mmol/l. RESULTS The rate of nocturnal confirmed… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 4 times. VIEW TWEETS

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 36 CITATIONS

Similar Papers

Loading similar papers…